Answers are grounded in this paper and cite their sources.
Tests a new targeted delivery system to enhance treatment efficacy in visceral leishmaniasis, indicating significant potential for resistance management.
This study presents the first fabrication of Arbortristoside-A (Arbor-A)-loaded PLGA nanoconstructs (Arbor-A-PNC) for targeted intramacrophagic delivery intended to enhance the therapeutic efficacy of Arbor-A in the treatment of visceral leishmaniasis (VL). VL treatment remains a formidable health challenge due to the parasites' intramacrophagic persistence, drug-induced toxicities, emerging drug resistance, and no vaccines in hand. Arbor-A, a bioactive iridoid glycoside naturally occurring in Nyctanthes arbor-tristis Linn., has shown potent leishmanicidal activity by inhibiting trypanothione reductase, a validated drug-target enzyme in Leishmania parasites, leading to redox homeostasis disruption, elevated ROS, cell membrane damage, and apoptotic-led parasitic death. Despite encouraging anti-VL potential, its further investigation remained unexplored, attributed to poor aqueous solubility posing a challenge in developing Arbor-A formulations. To address this and maximise Arbor-A- Leishmania parasite contact, this work introduces macrophage-targeted Arbor-A-PNC that have been systematically optimised through a Box–Behnken statistical design approach. The optimised nanoconstructs exhibited a spherical geometry, optimal size ( Z av = 166.25 ± 2.90 nm), monomodal dispersion (PDI = 0.111 ± 0.008), –11.75 ± 0.07 mV ζ-potential, 65.91 ± 12.47% Arbor-A entrapment and biphasic, sustained release governed by quasi-Fickian (n ˂ 0.43) diffusion kinetics. Mechanistic insights gained using flow cytometry and fluorescence imaging revealed its efficient intramacrophagic uptake, while cytotoxicity assays demonstrated toxicity reduction of free Arbor-A towards macrophages in vitro. Notably, the ex vivo infection assays showed its significant 9.97-fold higher efficacy compared to native Arbor-A against Leishmania donovani amastigotes. The study introduces a pioneering approach for the intramacrophagic delivery of plant-derived antileishmanial iridoid glycoside based on a nanotherapeutic platform, positioning nanoformulated Arbor-A as a prospective option to existing VL chemotherapeutics that are increasingly undermined by the emergence of drug resistance and systemic toxicities. • Black-sickness (VL) is a fatal infection with numerous challenges, calling innovative therapeutics. • PLGA-nanoconstructs entrapping Arbor-A, a leishmanicidal phytomedicinal lead, is developed via QbD. • Nanoconstructs exhibited a stronger ability to be uptaken by host-macrophages. • Nanoformulated Arbor-A achieved 9.97-fold higher efficacy in infection resolution ex vivo . • Arbor-A-PNC system holds a promising option to toxic & resistance facing VL chemotherapeutics.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: